GVK Bio has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to undertake drug discovery research and generate intellectual property (IP). Based on the research output, the company would file INDs (Investigative New Drug) with the US Food & Drug Administration. The work would be largely on drug candidates focused on pre-defined discovery targets. GVK Bio, the Hyderabad-based company, will utilise in-house capabilities in discovery chemistry, informatics, biology and toxicology to advance this collaborative programme expected to be between 2-3 years.
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/news/gvk-bio-wyeth-sign-drug-discovery-pact
[2] http://admin.indiaenvironmentportal.org.in/category/newspaper/business-line-new-delhi
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/intellectual-property-rights-ipr
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/hyderabad-d
